GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Total Current Liabilities

Vericel (Vericel) Total Current Liabilities : $36.5 Mil (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Vericel's total current liabilities for the quarter that ended in Mar. 2024 was $36.5

Vericel Total Current Liabilities Historical Data

The historical data trend for Vericel's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Total Current Liabilities Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.80 22.48 26.05 37.46 45.75

Vericel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.75 35.61 35.95 45.75 36.47

Vericel Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Vericel's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=26.302+6.187
+Other Current Liabilities+Current Deferred Liabilities
=13.26+0
=45.7

Vericel's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=23.132+6.012
+Other Current Liabilities+Current Deferred Liabilities
=7.326+0
=36.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Vericel Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Vericel's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel (Vericel) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Total Current Liabilities
Comparable Companies
JANX SMMT NTLA FTRE NVAX ARVN CLDX RYTM ADMA CGON OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ATQP:Germany
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Website
https://www.vcel.com
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019

Vericel (Vericel) Headlines

From GuruFocus

Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

By Marketwired • 09-28-2023

Vericel Announces U.S. Commercial Availability of NexoBrid� (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

By Marketwired • 09-20-2023

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

By sperokesalga sperokesalga • 02-28-2023

Brown Capital Management Small Company Fund Buys Ncino Inc, Duck Creek Technologies Inc, Vericel Corp, Sells Glaukos Corp, Proto Labs Inc, Alteryx Inc

By GuruFocus Research GuruFocus Editor • 12-13-2021

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

By Value_Insider Value_Insider • 10-26-2022

Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

By GuruFocusNews GuruFocusNews • 01-04-2022

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

By Value_Insider Value_Insider • 11-10-2022

Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

By sperokesalga sperokesalga • 02-09-2023

Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth

By GuruFocusNews GuruFocusNews • 02-02-2022

Insider Sell: Director Paul Wotton Offloads 5,000 Shares of Vericel Corp (VCEL)

By GuruFocus Research • 12-17-2023